Cerus Corp (CERS)
Cerus Corporation is a biomedical products company focused on developing and commercializing systems and solutions for blood safety. Its flagship product, the INTERCEPT Blood System, is designed to reduce the risk of transfusion-transmitted infections in blood components such as platelets, plasma, and(intended for red blood cells in some regions). Founded in 1991 and based in California, Cerus aims to enhance the safety and availability of blood products worldwide.
Company News
ASML reported strong Q2 results, but its stock fell in pre-market trading. Other companies like Cassava Sciences, Logistic Properties of the Americas, Five Below, Cerus, Clean Energy Fuels, and Spirit Airlines also saw their stocks decline.
The widely followed growth investor keeps making moves.
Cerus (CERS) delivered earnings and revenue surprises of 40% and 2.76%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?